Incept, LLC

The University of Texas System

Focal, Inc.

Genzyme Corporation

Tulavi Therapeutics, Inc.

Other

Access Closure, Inc.

Confluent Surgical, Inc.

Novocell, Inc.

Amarpreet S Sawhney

Jeffrey Alan Hubbell

Chandrashekhar Prabhakar Pathak

Neil P Desai

Patrick K Campbell

Arthur J Coury

Peter K Jarrett

Farhad Khosravi

Luis Z Avila

Shikha P Barman

Suresh Subraya Pai

Peter G Edelman

Rami El-Hayek

Jennifer L Hill-West

Jennifer L Hill

Charles D Blizzard

Mark T Kieras

Ronald S Rudowsky

Syed F Hossainy

David A Melanson

John C Spiridigliozzi

Stephen Jack Herman

Stephen D Goodrich

C Michael Philbrook

William H Ransone, Ii

Syed F A Hossainy

Steven L Bennett

Timothy S Jarrett

Michael J McGrath

Douglas J Weaver

Donald Leo Elbert

Scott Robert Sershen

Laurence A Roth

Dean M Pichon

Bradley C Poff

Andrew C Vanslette

Courtney A Rosales

Kevin M Berrigan

Sanghamitra Chowdhury

Fred H Co

Paul D Drumheller

Michael Bassett

Corinne Bright

Michelle D Lyman

Fei Yao

Yong Ren

Chandrashekar P Pathak

William C Nason

Peter Jarrett

Raymond Lareau

James Howard Dreher

David J Enscore

George E Selecman

Arthur Driscoll

David J Nedder

Donald L Elbert

Ankita D Desai

Thomas S Bromander

Douglas Billings

Hans Claesson

Kenneth M Martin

Jeffrey A Hubbell

Marc A Levine

Michelle D Powell

Patrick Campbell

Thomas Bromander

Douglas J K Weaver

Marc Alan Levine

Ken Martin

Sarah Guedez

Mukesh Singhal

Paul D Drumbeller

Michael J Mcgrath

Ankita Darshan Desai

Chandrashekhar P Pathak

William H Ii Ransone

Douglas JK Weaver

An embolization system and methods for controlling solidification of embolic compositions comprising a first and a second embolic component that react with each other in vivo at a target site to form an embolic material, with the embolic components being dilutable in physiological fluids so that they do not form an embolic composition at a site that is not desired.

Embolic compositions and methods

Methods are provided for making freeze dried hydrogel and structures therefrom that may be introduced into a patient's body for medical applications. Precursor components are combined to initiate crosslinking. The combined precursor components are placed in a chilled tray, and allowed to crosslink to a desired level of complete crosslinking before and/or after being placed onto the tray. The partially crosslinked hydrogel is frozen and freeze dried. After freeze drying, the hydrogel is conditioned to substantially complete crosslinking, and formed into one or more structures, e.g., plugs, hemostatic, or other medical devices. For example, the hydrogel may be cut, machined, rolled, folded, compressed, and/or cored into that may be loaded into delivery devices that may be introduced into a body to implant or otherwise deliver the structures into the body, e.g., to seal a puncture or other passage through tissue.

Superabsorbent, freeze dried hydrogels for medical applications

Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

Intracameral drug delivery depots

Disclosed are methods, devices and materials for the in situ formation of an implant for treating a nerve. A treatment site on a nerve is positioned within a cavity defined by a form. A transformable media is introduced into the form cavity to surround the treatment site. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the treatment site. The implant may be a growth inhibiting nerve cap to inhibit neuroma formation following planned or traumatic nerve injury, a growth permissive conduit for facilitating reconnection of a severed nerve, or an anchor for stabilizing a pain management electrode with respect to a nerve. Access to the nerve treatment site may be open surgical or percutaneous.

Methods for forming a nerve barrier

Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.

Devices for in situ formed nerve caps and/or nerve wraps

Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

Shape changing drug delivery devices and methods

Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking.

Medical organogel processes and compositions

Disclosed are methods, devices and materials for the in situ formation of a nerve cap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.

Methods and devices for in situ formed nerve cap

Implantable materials may be used as spacers for separating tissues to reduce a dose of radioactivity received by one of the tissues. Applications include introducing a hydrogel spacer to a position between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, Further, there may be a step of administering a dose of radioactivity to at least the first tissue location or the second tissue location and/or a step of visualizing margins of the hydrogel spacer. A hydrogel spacer may comprise a polysaccharide and a radioopaque agent and may be used for fiducial marking.

Implant and biodegradable tissue marker compositions and methods

Methods and devices for treating a luminal pathology affecting an anatomical lumen of a patient comprising forming, in situ, a continuous cohesive layer of covalently-crosslinked hydrogel in a luminal wall of the anatomical lumen.

Extra luminal scaffold

Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

Drug delivery from hydrogels

Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel for controlled release of a therapeutic agent.

Hydrogel polymeric compositions and methods

Implantable materials visible under ultrasound may be delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.

Echolucent implant composition and methods

Growing community of inventors

Lexington, MA, United States of America

Amarpreet S Sawhney